Jiangxi Sanxin Medtec Co (300453) Fair Value & Analysis
Healthcare · CN · Market cap 4.8B CNY
Analysis
Jiangxi Sanxin Medtec Co (300453) currently trades at ¥9.23, while our model-based Fair Value estimate is ¥11.06 — implying the stock looks roughly 19.8% undervalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Jiangxi Sanxin Medtec Co.,Ltd. engages in the research and development, manufacture, sale, and service of medical devices. The company offers infusion and cardiothoracic surgery products; and blood purification products, such as dialysate filter, dialysis indwelling needle, disposable biological protein glue dispenser, dialysis fluid filter, continuous blood purification pipeline and accessories, hemodialysis concentrate, hemodialysis water production systems, hemodialysis machines, centralized liquid supply system, dialysis care package, central venous catheter kits, arteriovenous spikes, accessories tubing for HDF, dialysate filters, hemodialysis dry powders and concentrates, disposable hollow fiber dialyzers, blood purification and fluid replacement pipeline, and hemodialysis tubing. It also provides pre filled catheter flushing device, heparin cap, sterile needle, disposable filtration infusion set, disposable light shielded precision filtration infusion set, blood transfusion d…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.